» Articles » PMID: 25318883

Carbohydrate Antigens As Potential Biomarkers for the Malignancy in Patients with Idiopathic Deep Venous Thrombosis: a Retrospective Cohort Study

Overview
Specialty General Medicine
Date 2014 Oct 17
PMID 25318883
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

A variety of biomarkers have been identified in recent prospective and retrospective reports as being potentially predictive of venous thromboembolis (VTE), particularly idiopathic deep venous thrombosis (IDVT). This study identified a serum tumor biomarker for early screening of IDVT. A total of 128 IDVT patients (54 females and 74 males; average age: 50.9±17.4 years) were included. Carcinoembryonic antigen (CEA), ferritin, β2-microglobulin, cancer antigen (CA) 125, CA 15-3, CA 19-9, squamous cell carcinoma antigen (SCC), alpha-fetoprotein (AFP), prostate specific antigen (PSA), free PSA (f-PSA), and beta-human chorionic gonadotropin (β-HCG) in patients with IDVT were detected. Malignancies were histo- or cytopathologically confirmed. Of the 128 IDVT patients, 16 (12.5%) were found to have malignancies. Serum CEA, CA 125, CA 15-3, and CA 19-9 were found to be helpful for detecting malignancies in IDVT patients. Our study revealed a positive association between these markers and tumors in IDVT patients. On the other hand, SCC and AFP were not sensitive enough to be markers for detecting tumors in patients with IDVT. No significant differences were found in positive rates of ferritin and β2-microglobulin between tumor and non-tumor groups, and no significant difference exists in serum levels of ferritin and β2-microglobulin between the two groups. Carbohydrate antigens, CA 15-3 in particular, may be useful for differential diagnosis and prediction of malignancies in patients with IDVT.

Citing Articles

Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.

Lee L, Nagarajan C, Tan C, Ng H Front Cardiovasc Med. 2021; 8:669288.

PMID: 34095258 PMC: 8175646. DOI: 10.3389/fcvm.2021.669288.


Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery.

Li Y, Shen L, Ding J, Xie D, Yang J, Zhao Y Transl Lung Cancer Res. 2021; 10(4):1829-1840.

PMID: 34012796 PMC: 8107740. DOI: 10.21037/tlcr-21-109.


Selected Tumour Biomarker Levels in Sheep with Pulmonary Adenomatosis.

Ozkan C, Yildirim S, Huyut Z, Ozbek M J Vet Res. 2020; 64(1):39-44.

PMID: 32258798 PMC: 7105990. DOI: 10.2478/jvetres-2020-0017.

References
1.
Chronowski G, Wilder R, Tucker S, Ha C, Sarris A, Hagemeister F . An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002; 95(12):2534-8. DOI: 10.1002/cncr.10998. View

2.
Akagi J, Takai E, Tamori Y, Nakagawa K, Ogawa M . CA19-9 epitope a possible marker for MUC-1/Y protein. Int J Oncol. 2001; 18(5):1085-91. DOI: 10.3892/ijo.18.5.1085. View

3.
Xie J, Yi Q . Beta2-microglobulin as a potential initiator of inflammatory responses. Trends Immunol. 2003; 24(5):228-9; author reply 229-30. DOI: 10.1016/s1471-4906(03)00076-0. View

4.
Khorana A, Francis C, Culakova E, Kuderer N, Lyman G . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-4. DOI: 10.1111/j.1538-7836.2007.02374.x. View

5.
Oefelein M, Brant M, Crotty K . Idiopathic thromboembolism as the presenting sign of occult prostate cancer. Urology. 1998; 51(5):775-80. DOI: 10.1016/s0090-4295(98)00008-9. View